Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The genomics landscape was active in Q2 2022, with scores increasing for several companies. This includes Merck & Co, whose score increased to 4 due to an increase in forecasted sales for several Phase II candidates, including its oncolytic vaccine Cavatak (gebasaxturev), an mRNA vaccine, and its recombinant vector vaccine V-184 for Chikungunya fever.

In Regenerative Medicine, AstraZeneca saw an increase in its score due to forecasted global sales for its oligonucleotide AZD-8601 and an increase in posted jobs in Q2 2022. AbbVie’s score for nanotechnology was changed to 5 due to an increase in forecasted global sales for its antibody-drug conjugates (ADC) ABBV-154 and telisotuzumab vedotin.

Key themes Genomics, Nanotechnology, and Rare Disease

The pharmaceutical drug development sector scorecard report offers in-depth research into a specific theme (such as AI or cybersecurity). The report identifies winners and losers based on technology leadership, market position, and other factors. It also covers all themes within a sector, giving readers a strong sense of how everything fits together and how conflicting themes might interact with one another. Moreover, each sector scorecard identifies the companies that are most likely to succeed in a world filled with disruptive threats.

Pharmaceutical Drug Development – Key Themes

Some of the key themes that have impacted the drug development thematic scorecard in Q2 2022 are as follows:


Cadila Pharmaceuticals’s score has been increased from 1 to 3 following the launch of its recombinant vector vaccine for rabies, ThRabis, in April 2022. This is the world’s first three-dose rabies vaccine, with all existing regimens requiring five doses.


In June 2022, it was rumored that Merck & Co could acquire Seagen, a leader in the development of ADCs in oncology. If this acquisition is completed, Merck & Co’s score for Nanotechnology would increase to 5.

Rare Disease

GSK’s score for Rare Disease has been increased from 4 to 5 due to the announcement in April 2022 that it was to acquire Sierra Oncology. Sierra Oncology’s momelotinib dihydrochloride is in late-stage development for the treatment of myelofibrosis, thrombocythemia myelofibrosis, and post-polycythemia vera myelofibrosis in the US and Europe.

For more insights on the key themes impacting the drug development thematic scorecard, download a free report sample


  • GlobalData’s Drug Development Scorecard provides a top-down, comprehensive outlook for the key players in the drug development sector over the next two to four years, based on 10 of the major themes set to transform the landscape.
  • These 10 themes are Immuno-oncology, Regenerative Medicine, Precision & Personalized Medicine, Rare Disease, Biosimilars, Genomics, Microbiome, Nanotechnology, Strategic Alliances, Artificial Intelligence,
  • The scorecard includes 53 companies from across the industry, including biopharmaceutical companies, biosimilar, and generic manufacturers, contract development and manufacturing organizations (CDMOs), and contract research organizations (CROs).
  • It is important to note that this scorecard is not an assessment of the current performance of a company in a theme, but a view of future performance based on current levels of activity and investment.
  • The methodology section contains information on what data sources were used to generate the thematic scores for each company.
  • The scorecard is live on the PIC and will be updated quarterly.

Reasons to Buy

  • Identify the key drug development themes for the next 2-4 years and learn how they will impact the market.
  • Understand which key themes should be addressed to drive the share price.
  • Understand which companies are best positioned for success within critical themes and why.
  • Learn which companies have underinvested in key themes and are most vulnerable to disruption.
  • Help companies adapt their strategy to anticipate and benefit from these themes as they play out.
  • Help identify future winners and losers in drug development to inform partnership strategies.

Table of Contents

Executive Summary


• Pharma Theme Map

Drug Development Scorecard: Key Q2 2022 Updates

• Company Screen

• Thematic Screen

• Valuation Screen

Our Thematic Research Methodology

• How Our Pharma Scores Are Generated

Related Reports

About the Authors

About GlobalData

Frequently asked questions

Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research in real time.

  • Access a live Pharmaceutical Drug Development Sector Scorecard, Q2 2022 Update – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.